JP2003000270A5 - - Google Patents

Claims (19)

  A peptide comprising the amino acid sequence of any one of SEQ ID NO: 1 to SEQ ID NO: 17 in the sequence listing having an HLA-A24 molecule binding motif.   A medicament comprising the peptide according to claim 1.   A cancer vaccine comprising the peptide according to claim 1.   The pharmaceutical or cancer vaccine according to claim 2 or 3, which is used for the treatment of lung cancer or renal cancer.   The inducer of the cytotoxic T cell containing the peptide of Claim 1.   A method for inducing cytotoxic T cells, comprising using the peptide according to claim 1.   A polynucleotide encoding the peptide of claim 1 or a complementary strand thereof.   A polynucleotide comprising the polynucleotide encoding the peptide of claim 1 as a part thereof, the polynucleotide of any one of SEQ ID NO: 767 to SEQ ID NO: 774 or a complementary strand thereof.   The polynucleotide or a complementary strand thereof according to claim 8, wherein the peptide is a peptide that induces cytotoxic T cells and / or is recognized by cytotoxic T cells.   A polynucleotide that hybridizes with the polynucleotide of any one of claims 7 to 9 or a complementary strand thereof under stringent conditions.   A recombinant vector containing the polynucleotide according to any one of claims 7 to 10 or a complementary strand thereof.   The recombinant vector according to claim 11, wherein the recombinant vector is an expression recombinant vector.   A transformant into which the recombinant vector according to claim 11 or 12 has been introduced.   A method for producing a peptide encoded by the peptide according to claim 1 or the polynucleotide according to any one of claims 8 to 10, comprising a step of culturing the transformant according to claim 13.   An antibody that immunologically recognizes the peptide according to claim 1.   11. A compound that interacts with the peptide of claim 1 and / or HLA-A24 to enhance recognition of the peptide by at least HLA-A24-restricted cytotoxic T cells, and / or any of claims 7-10. A method for identifying a compound that interacts with the polynucleotide according to claim 1 or its complementary strand to enhance its expression, comprising the peptide according to claim 1, or the claim according to any one of claims 7 to 10. A polynucleotide or a complementary strand thereof, at least one of a recombinant vector according to claim 11 or 12, a transformant according to claim 13, or an antibody according to claim 15 is used. Method.   The peptide according to claim 1, the polynucleotide according to any one of claims 7 to 10 or a complementary strand thereof, the recombinant vector according to claim 11 or 12, the transformant according to claim 13, A pharmaceutical composition used for cancer treatment, comprising at least one of the antibodies according to claim 15.   A method for quantitatively or qualitatively measuring the peptide according to claim 1 or the polynucleotide according to any one of claims 7 to 10.   A peptide according to claim 1, a polynucleotide according to any one of claims 7 to 10, a recombinant vector according to claim 11 or 12, a transformant according to claim 13, or a claim 15 A reagent kit comprising at least one of the antibodies described in 1.